Critical Role of AT₁ Receptor Expression After Ischemia/Reperfusion in Isolated Rat Hearts

Beneficial Effect of Antisense Oligodeoxynucleotides Directed at AT₁ Receptor mRNA

From the Departments of Medicine, Pediatrics, and Physiology, University of Florida, and the VA Medical Center, Gainesville, Fla.

Correspondence to J.L. Mehta, MD, PhD, Department of Medicine, University of Florida College of Medicine, 1600 Archer Rd, PO Box 100277 JHMHC, Gainesville, FL 32610. E-mail mehta{at}medmac.ufl.edu

Abstract—To examine the relevance of angiotensin II type 1 receptor (AT₁R) expression in the determination of myocardial function after ischemia/reperfusion, Sprague-Dawley rats were treated intravenously with antisense oligodeoxynucleotides (AS-ODNs) directed at AT₁R mRNA (100 µg/rat, n=9) or scrambled antisense oligodeoxynucleotides (Scr-ODNs, 100 µg/rat, n=6). Both AS-ODNs and Scr-ODNs were given along with 300 µg/rat of liposome DOTAP/DOPE, a positive electron carrier (wt:wt=1:1). The hearts from AS-ODN– or Scr-ODN–treated rats were excised 24 hours later, perfused in vitro, and subjected to 25 minutes of global ischemia followed by 30 minutes of reperfusion. Parallel groups of rats were given the specific AT₁R antagonist losartan (10 mg/kg IV, n=6) or saline (n=7) 4 to 6 hours before excising the hearts. Ischemia/reperfusion resulted in a significant increase in myocardial AT₁R expression (autoradiography and binding assay) and myocardial dysfunction, indicated by increases in coronary perfusion pressure and left ventricular end-diastolic pressure and a decrease in developed left ventricular pressure (all P<0.01 versus baseline) in the saline-treated group. AT₁R protein and mRNA levels also increased in ischemic/reperfused myocardial tissues. Administration of AS-ODNs or losartan, but not Scr-ODNs, preserved myocardial function and blocked the increased AT₁R binding after ischemia/reperfusion (both P<0.01). Myocardial AT₁R mRNA levels were not affected by either AS-ODNs or losartan, and the AT₁R protein levels were significantly reduced by AS-ODN, but not losartan, treatment. Plasma angiotensin II levels increased after administration of losartan but not after administration of AS-ODNs. These observations imply a critical role of AT₁R upregulation in determining myocardial function immediately after ischemia/reperfusion. AS-ODNs to AT₁R mRNA may be more beneficial than losartan, because losartan does not affect the plasma angiotensin II level. The sustained increase in AT₁R mRNA, but diminished protein expression, in rat hearts treated with AS-ODNs suggests that AS-ODNs block AT₁R at the translational level.

Key Words: angiotensin II • antisense • AT₁ receptor • ischemia/reperfusion • losartan • mRNA

This article has been cited by other articles:

				B. Molavi, J. Chen, and J. L. Mehta Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H687 - H693. [Abstract] [Full Text] [PDF]

				G.-Q. Zhu, L. Gao, Y. Li, K. P. Patel, I. H. Zucker, and W. Wang AT1 receptor mRNA antisense normalizes enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1828 - H1835. [Abstract] [Full Text] [PDF]

				P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]

				D. Kumar, V. Menon, W. R. Ford, A. S. Clanachan, and B. I. Jugdutt Effect of Angiotensin II lype 2 Receptor Blockade on Activation of Mitogen-Activated Protein Kinases after Ischemia-Reperfusion in Isolated Working Rat Hearts Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 285 - 296. [Abstract] [PDF]

				M. Iurlaro, M. Scatena, W.-H. Zhu, E. Fogel, S. L. Wieting, and R. F. Nicosia Rat aorta-derived mural precursor cells express the Tie2 receptor and respond directly to stimulation by angiopoietins J. Cell Sci., September 1, 2003; 116(17): 3635 - 3643. [Abstract] [Full Text] [PDF]

				F. S. Gragasin, Y. Xu, I. A. Arenas, N. Kainth, and S. T. Davidge Estrogen Reduces Angiotensin II-Induced Nitric Oxide Synthase and NAD(P)H Oxidase Expression in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., January 1, 2003; 23(1): 38 - 44. [Abstract] [Full Text] [PDF]

				Y. Xu, D. Kumar, J. R. B. Dyck, W. R. Ford, A. S. Clanachan, G. D. Lopaschuk, and B. I. Jugdutt AT1 and AT2 receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1206 - H1215. [Abstract] [Full Text] [PDF]

				Y. Tang, M. Jackson, K. Qian, and M. I. Phillips Hypoxia Inducible Double Plasmid System for Myocardial Ischemia Gene Therapy Hypertension, February 1, 2002; 39(2): 695 - 698. [Abstract] [Full Text] [PDF]

				S.-I. Suga, M. I. Phillips, P. E. Ray, J. A. Raleigh, C. P. Vio, Y.-G. Kim, M. Mazzali, K. L. Gordon, J. Hughes, and R. J. Johnson Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity Am J Physiol Renal Physiol, October 1, 2001; 281(4): F620 - F629. [Abstract] [Full Text] [PDF]

				B. Yang, L. Graham, S. Dikalov, R. P. Mason, J. R. Falck, J. K. Liao, and D. C. Zeldin Overexpression of Cytochrome P450 CYP2J2 Protects against Hypoxia-Reoxygenation Injury in Cultured Bovine Aortic Endothelial Cells Mol. Pharmacol., August 1, 2001; 60(2): 310 - 320. [Abstract] [Full Text] [PDF]

				R. Moudgil, Y. Xu, V. Menon, and B. I. Jugdutt Effect of Chronic AT1 Receptor Antagonism on Postischemic Functional Recovery and AT1/AT2 Receptor Proteins in Isolated Working Rat Hearts Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 183 - 188. [Abstract] [PDF]

				D. Li, T. Saldeen, F. Romeo, and J. L. Mehta Oxidized LDL Upregulates Angiotensin II Type 1 Receptor Expression in Cultured Human Coronary Artery Endothelial Cells : The Potential Role of Transcription Factor NF-{kappa}B Circulation, October 17, 2000; 102(16): 1970 - 1976. [Abstract] [Full Text] [PDF]

				Y. Xu, A. S. Clanachan, and B. I. Jugdutt Enhanced Expression of Angiotensin II Type 2 Receptor, Inositol 1,4,5-Trisphosphate Receptor, and Protein Kinase C{epsilon} During Cardioprotection Induced by Angiotensin II Type 2 Receptor Blockade Hypertension, October 1, 2000; 36(4): 506 - 510. [Abstract] [Full Text] [PDF]

				H. Chen, Y. C. Zhang, D. Li, M. I. Phillips, P. Mehta, M. Shi, and J. L. Mehta Protection against Myocardial Dysfunction Induced by Global Ischemia-Reperfusion by Antisense-Oligodeoxynucleotides Directed at beta 1-Adrenoceptor mRNA J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 722 - 727. [Abstract] [Full Text]

				D. W. O'Brien, Y. Xu, V. Menon, and B. I. Jugdutt Efficacy of Pretreatment With the Angiotensin II Type 1 Receptor Blocker UP269-6 and Losartan in the Dog: Effect on Hemodynamics and Ischemia-Reperfusion Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 129 - 137. [Abstract] [PDF]

				W. R. Ford, A. S. Clanachan, and B. I. Jugdutt Characterization of Cardioprotection Mediated by AT2 Receptor Antagonism After Ischemia-Reperfusion in Isolated Working Rat Hearts Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 211 - 221. [Abstract] [PDF]

				B. I. Jugdutt, Yi Xu, M. Balghith, R. Moudgil, and V. Menon Cardioprotection Induced by AT1R Blockade After Reperfused Myocardial Infarction: Association With Regional Increase in AT2R, IP3R and PKC{varepsilon} Proteins and cGMP Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 301 - 311. [Abstract] [PDF]

				K. L. Butler, A. H. Huang, and J. K. Gwathmey AT1-receptor blockade enhances ischemic preconditioning in hypertrophied rat myocardium Am J Physiol Heart Circ Physiol, December 1, 1999; 277(6): H2482 - H2487. [Abstract] [Full Text] [PDF]

				J.L. Mehta and I. Phillips Increase in Plasma Angiotensin II Levels After Chemical Blockade of AT1 Receptor Blockers, But Not With Antisense Oligodeoxynucleotide Directed at AT1 Receptor mRNA: A Major Benefit of Gene Therapy Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(3): 135 - 136. [PDF]